Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.
SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Location: United States, Illinois, Chicago
Member count: 51-200
Founded date: 2011
Investors 3
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 11.12.2021 | Exicure, I... | Exicure, Inc. announced a prep... | - | - | marketscre... |
| 01.12.2017 | Chicago St... | Chicago-area tech and startup ... | Stories F... | - | bizjournal... |
| 06.11.2017 | Exicure ra... | Exicure has pulled in more mon... | Biotech | - | fiercebiot... |
| 14.10.2017 | A biotech ... | David Giljohann Exicure CEO D... | - | - | businessin... |
| 12.12.2016 | Purdue and... | For that investment, Purdue ge... | - | - | medcitynew... |
| - | Purdue and... | A startup dream has been reali... | - | - | medcitynew... |